Drugs Made in America Acquisition II amends CFO and CEO pay, adds 425,000 share awards
A blank-check company disclosed two agreements dated April 22, 2026: an updated consulting statement of work for its CFO, Saleem Elmasri, and a compensation agreement for CEO Roger Bendelac. Both provide for ordinary share awards that are earned on signing a definitive business combination agreement and issued at closing of the initial business combination, which would dilute existing shareholders.
Key points
- Updated statement of work with Titan Advisory Services LLC gives Elmasri 175,000 ordinary shares in place of the 100,000 shares in the original SoW, issued within ten days after closing of the initial business combination.
- CEO compensation agreement with Aleutian Equity Holdings LLC sets Bendelac's pay at $4,500 per month, of which $2,500 is payable currently and up to $2,000 may be deferred.
- Bendelac is also entitled to 250,000 ordinary shares, earned on execution of a definitive agreement and issued at closing of the initial business combination.
- Deferred amounts accrue as binding obligations of the Company.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.